IL-33 activates tumor-associated macrophages and dendritic cells by binding to its receptor, ST2, triggering the release of abundant Th2 cytokines, including IL-10, IL-4, and IL-13, which inhibit immune cell responses, hampering tumor clearance and control. The gene discussed is IL13; the disease is neoplasm.